WO2025057106 - PROCESS AND COMPOUNDS FOR PREPARING CAMONSERTIB AND ITS SALTS
National phase entry is expected:
Publication Number
WO/2025/057106
Publication Date
20.03.2025
International Application No.
PCT/IB2024/058889
International Filing Date
12.09.2024
Title **
[English]
PROCESS AND COMPOUNDS FOR PREPARING CAMONSERTIB AND ITS SALTS
[French]
PROCÉDÉ ET COMPOSÉS DE PRÉPARATION DE CAMONSERTIB ET DE SES SELS
Applicants **
REPARE THERAPEUTICS INC.
Inventors
DORICH, Stephane
FÉDOU, Nicolas Mickaël
BEAULIEU, Patrick
BERNATCHEZ, Michel
Priority Data
23196700.1
12.09.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3869 | |
| EPO | Filing, Examination, Granting | 35324 | |
| Japan | Filing, Examination, Granting | 3365 | |
| South Korea | Filing, Examination, Granting | 4473 | |
| USA | Filing, Examination, Granting | 21190 |
Total:
68,221
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
]pyridin-4-yl}-8-oxabicyclo[3.2.1]octan-3-ol (camonsertib) and pharmaceutically acceptable salts thereof, which are useful as pharmaceutically active anti-cancer compounds.[French]
]pyridin-4-yl}-8-oxabicyclo[3.2.1]octan-3-ol (camonsertib) et de sels pharmaceutiquement acceptables de celui-ci, qui sont utiles en tant que composés anticancéreux pharmaceutiquement actifs.